PD 168368 是一种有效的、竞争性的选择性神经调节蛋白 B 受体 (NMB-R) 拮抗剂,Ki为 15-45 nM。 PD 168368 是神经调节素 B 受体(NMBR; IC50=96 nM)和胃泌素释放肽受体 (GRPR; IC50=3500 nM))的双重拮抗剂。PD 168368 还是一种FPR1/FPR2/FPR3的混合激动剂,EC50分别为 0.57、0.24 和 2.7 nM。
生物活性 | PD 168368 is a potent, competitive, and selectiveneuromedin B receptor(NMB-R) antagonist with theKiof 15–45 nM[1]. PD 168368 is neuromedin B receptor (NMBR;IC50=96 nM) / gastrin-releasing peptide receptor (GRPRIC50=3500 nM) antagonist[2]. PD 168368 also is a mixedFPR1/FPR2/FPR3agonist withEC50s of 0.57, 0.24, and 2.7 nM, respectively[3]. |
体外研究 (In Vitro) | PD 168368 (PD168368) is highly active and stimulated [Ca2+]Irelease in human neutrophils with EC50values in the nanomolar range[3]. PD 168368 (PD168368) suppresses migration and invasion of the human breast cancer cell line MDA-MB-231. PD 168368 reduces epithelial-mesenchymal transition (EMT) of breast cancer cells by E-cadherin upregulation and vimentin downregulation. PD 168368 (5 μM) inhibits migration and invasiveness in breast cancer cells[4]. PD 168368 (10 μM) suppresses the activation of mTOR/p70S6K/4EBP1 and AKT/GSK-3β pathways in breast cancer cells[4].
Cell Viability Assay[4] Cell Line: | Human breast cancer cell line MDA-MB-231 | Concentration: | 5 μM | Incubation Time: | 24 hours | Result: | Clearly decreased the migratory ability of MDA-MB-231 cells in a Boyden chamber migration assay. |
Cell Viability Assay[4] Cell Line: | MDA-MB-231 cells | Concentration: | 10 μM | Incubation Time: | 0, 0.5, 1, 2, 4, 8, and 16 hours | Result: | Decreased phosphorylation levels of mTOR, p70S6K, 4EBP1, AKT and GSK-3β in a time-dependent manner. |
|
体内研究 (In Vivo) | PD 168368 (PD168368) potently inhibits in vivo metastasis of breast cancer. PD 168368 (1.2 mg/kg; intraperitoneal injection for 30 days) inhibits metastasis of breast cancer in mice[4].
Animal Model: | Female BALB/c-nude mice (age 8-10 weeks) bearing MDA-MB-231 xenograft model[4] | Dosage: | 1.2 mg/kg | Administration: | Intraperitoneal injection for 30 days | Result: | No metastatic tumor nodules were observed in lungs of PD 168368-treated mice compared to PEG-injected mice. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 30 mg/mL(54.09 mM;Need ultrasonic and warming) DMF : 10 mg/mL(18.03 mM;Need ultrasonic and warming) 配制储备液 1 mM | 1.8030 mL | 9.0149 mL | 18.0297 mL | 5 mM | 0.3606 mL | 1.8030 mL | 3.6059 mL | 10 mM | 0.1803 mL | 0.9015 mL | 1.8030 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 |